To amend the Public Health Service Act to require reporting by drug manufacturers to increase transparency in drug pricing, and for other purposes.
Transparent Drug Pricing Act of 2017
This bill requires drug manufacturers to report specified financial and sales information, including drug pricing, tax credit, and patent information; violations are subject to civil penalties.
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line